文献速递青光眼

CIGTS研究中青光眼对侧眼与 Study Eye 疾病轨迹关联及对侧眼治疗需求分析

Association of Fellow Eye With Study Eye Disease Trajectories and Need for Fellow Eye Treatment in Collaborative Initial Glaucoma Treatment Study (CIGTS) Participants.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

该事后分析纳入607例新诊断开角型青光眼患者,随访至11年,研究Study Eye(SE)初始治疗后对侧眼(FE)需治疗的时间及双眼进展速率一致性。结果显示FE治疗概率1年0.57、7年0.68;SE与已治疗FE的平均偏差(MD)斜率相关系数达0.71–0.73,提示SE变化可预示FE变化,需密切监测。

要点

  • 新诊断开角型青光眼患者中47.9%的对侧眼在基线即需治疗,7年时约三分之二患者双眼均接受治疗。
  • SE与已治疗FE的MD斜率相关系数为0.71–0.73,SE进展可预示FE进展。
  • 高龄、高血压、高眼压、大杯盘比及更差MD与FE治疗风险增加显著相关。

核心结论

  • 新诊断开角型青光眼中近半数基线时双眼均已治疗,7年后约三分之二患者接受双侧治疗。
  • SE与已治疗FE的MD斜率高度相关,提示SE变化可预示FE变化,值得密切监测。
  • 可改变的影响FE治疗风险因素包括高血压和眼压。

研究设计与样本

  • CIGTS研究的事后分析,纳入607例新诊断开角型青光眼患者,随访至11年。
  • 基线指定SE并随机接受药物或手术治疗,FE按方案符合条件时或由医生决定治疗。
  • 采用生存分析估计FE治疗概率及预测因素,线性回归计算MD和IOP的眼别斜率并计算双眼相关性。

主要发现

  • 291只FE(47.9%)在基线即治疗,123只(20.3%)最终治疗,193只(31.8%)从未治疗。
  • FE因开角型青光眼治疗概率随机化后1年为0.57,7年为0.68。
  • SE与初始、最终、从未治疗FE的MD斜率相关系数分别为0.73、0.71、0.34;IOP斜率相关系数分别为0.57、0.24、0。

关键数值与推荐

  • FE治疗概率:1年0.57,7年0.68。
  • SE与已治疗FE的MD斜率相关系数0.71–0.73,IOP斜率相关系数0.24–0.57。

临床怎么用

  • 对SE进展较快的青光眼患者,应密切监测FE,因其进展轨迹高度相关。
  • 控制高血压和眼压可能降低FE治疗风险。
  • 高龄、大杯盘比、差MD等基线特征提示FE需更早干预。

局限性

  • 为事后分析,FE治疗并非完全按方案随机,存在医生 discretion。
  • 数据收集于1993–2004年,分析于2012–2018年,结论外推需谨慎。
  • 未报告FE治疗对长期视力结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinicians would benefit from knowing the association of glaucomatous change in 2 eyes of the same patient. OBJECTIVE: To estimate the time between initial glaucoma treatment of the study eye (SE) and the need for treatment of the fellow eye (FE) and to ascertain the concordance between rates of progression in SEs and FEs. DESIGN, SETTING, AND PARTICIPANTS: In this post hoc analysis of participants from the Collaborative Initial Glaucoma Treatment Study, 607 participants with newly diagnosed open-angle glaucoma in 1 or both eyes were followed up for up to 11 years. An SE was designated at baseline and randomized to medical or surgical treatment. By protocol, FEs were treated when eligible or at physician discretion. Survival analysis methods were used to estimate the probability of FE treatment over time and to test baseline and time-dependent predictors of treatment. Disease trajectory was calculated with linear regression as the patient eye-specific slopes of mean deviation (MD) and intraocular pressure (IOP) over time, and correlations between SE and FE trajectories were calculated. Data were collected from October 1993 to December 2004. Data were analyzed from September 2012 to May 2018. MAIN OUTCOMES AND MEASURES: Time to FE treatment and slopes over time of MD and IOP in SEs and FEs. RESULTS: Of the 607 included patients, 334 (55.0%) were male and 337 (55.5%) were white, and the mean (SD) age was 58.0 (10.9) years. A total of 291 FEs (47.9%) were treated at baseline, 123 (20.3%) were eventually treated, and 193 (31.8%) never received treatment. The probability of FE treatment for open-angle glaucoma was 0.57 at 1 year and 0.68 at 7 years after randomization. Characteristics significantly associated with an increased hazard of FE treatment included older age (hazard ratio [HR], 1.33; 95% CI, 1.08-1.64; P = .007), hypertension (HR, 1.76; 95% CI, 1.16-2.67; P = .008), higher IOP (HR, 1.24; 95% CI, 1.20-1.29; P < .001), large cup-disc ratio (HR, 1.40; 95% CI, 1.23-1.58; P < .001), and worse MD. Correlations in MD slopes between SEs and FEs initially, eventually, and never treated were 0.73, 0.71, and 0.34, respectively. Comparable correlations in IOP slopes were 0.57, 0.24, and 0, respectively. CONCLUSIONS AND RELEVANCE: Among patients with newly diagnosed open-angle glaucoma, almost half had initial treatment of both eyes. After 7 years, approximately two-thirds of patients had bilateral treatment. Of the variables predictive of FE treatment, modifiable factors included hypertension and IOP. Slopes of MD were similar between SEs and treated FEs. This implies that SE change is a harbinger of FE change and therefore warrants close surveillance.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Niziol LM, Gillespie BW, Musch DC, et al. Association of Fellow Eye With Study Eye Disease Trajectories and Need for Fellow Eye Treatment in Collaborative Initial Glaucoma Treatment Study (CIGTS) Participants. JAMA Ophthalmol. 2018. PMID: 30098162. doi:10.1001/jamaophthalmol.2018.3274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。